COMMUNIQUÉS West-GlobeNewswire

Momenta Pharmaceuticals Provides Update on US Regulatory Strategy for M923, Proposed Biosimilar to HUMIRA®

03/12/2018 - 22:05

CAMBRIDGE, Mass., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company with a validated scientific platform focused on discovering and developing novel therapeutics to [...]

Paratek Pharmaceuticals Files Two Patent Term Extensions in the United States; Expects NUZYRA™ Patent Protection Exclusivity Until at Least October 2030

03/12/2018 - 22:01

BOSTON, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today [...]

University Medical Centre Groningen chooses TAT-5000 of Exergen Medical as standard thermometer throughout hospital

03/12/2018 - 21:54

WATERTOWN, Mass. and GRONINGEN, The Netherlands, Dec. 03, 2018 (GLOBE NEWSWIRE) -- University Medical Centre Groningen has decided to standardize on the TAT-5000 thermometer of Exergen Medical. The well-known university [...]

Nextech and Red Spot Interactive Partner to Enhance Provider Retention and Patient Acquisition

03/12/2018 - 21:47

Product integration delivers tools to encourage profit driven business decisions for specialty healthcare practices TAMPA, Fla., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Nextech Systems , a leading provider of healthcare [...]

INNATE PHARMA : Updated results that support advancement of IPH4102 in refractory Sézary syndrome at ASH 2018

03/12/2018 - 20:46

INNATE PHARMA ANNOUNCES UPDATED RESULTS THAT SUPPORT ADVANCEMENT OF IPH4102 IN REFRACTORY SÉZARY SYNDROME AT THE AMERICAN SOCIETY OF HEMATOLOGY (ASH) 2018 ANNUAL MEETING Differentiating profile of IPH4102 confirmed: [...]

INNATE PHARMA : ASH, présentation de résultats d'IPH4102 chez les patients présentant un syndrome de Sézary réfractaire et poursuite du développement en phase II dans les lymphomes de type T

03/12/2018 - 20:46

CONGRÈS ANNUEL DE LA SOCIÉTÉ AMERICAINE D'HÉMATOLOGIE (ASH) 2018 : PRÉSENTATION DE NOUVEAUX RÉSULTATS D'IPH4102 CHEZ LES PATIENTS PRÉSENTANT UN SYNDROME DE SÉZARY RÉFRACTAIRE ET POURSUITE DU DÉVELOPPEMENT EN PHASE II [...]

BeiGene Presents Clinical Results of Tislelizumab in Relapsed/Refractory Classical Hodgkin’s Lymphoma at the 60th American Society of Hematology Annual Meeting

03/12/2018 - 20:15

Company to Host Investor Meeting and Webcast Today, December 3, at 8 pm PST BEIJING, China and CAMBRIDGE, Mass., Dec. 03, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage [...]

Hybrigenics (ALHYG) : Moonstone Investments a soumis une proposition de transaction, sous conditions suspensives.

03/12/2018 - 20:12

C ette proposition, crédible et créatrice de valeur, vise à donner un nouvel espoir à la société Hybrigenics et ses actionnaires et constitue une alternative à la dissolution anticipée. Amsterdam, le 3 décembre 2018 Le [...]

CAPS® Teams with Kit Check to Add Serialized Radio Frequency Identification (RFID) Tags on Pre-Filled Syringes

03/12/2018 - 19:08

BETHLEHEM, Pa., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Central Admixture Pharmacy Services, Inc. (CAPS) has announced a collaborative agreement to embed Kit Check’s serialized RFID tags on CAPS’ pre-filled anesthesia [...]

Exeter Hospital joins North American Partners in Anesthesia

03/12/2018 - 19:02

MELVILLE, N.Y., Dec. 03, 2018 (GLOBE NEWSWIRE) -- North American Partners in Anesthesia (NAPA) , one of the leading single-specialty anesthesia and perioperative management companies in the US, recently expanded [...]

Apellis Pharmaceuticals Presents New Data from Ongoing APL-2 Phase 2 Study in Patients with Cold Agglutinin Disease and Warm Antibody Autoimmune Hemolytic Anemia at ASH

03/12/2018 - 19:01

- New data on APL-2 demonstrate improvements in hematological parameters in cold agglutinin disease (CAD) and warm antibody autoimmune hemolytic anemia (wAIHA) - CAD patients treated with APL-2 had an improvement in [...]

Phase 2 Interim Data Evaluating the Combination of Pracinostat and Azacitidine in Patients with Myelodysplastic Syndrome Presented at the 2018 American Society of Hematology Annual Meeting

03/12/2018 - 18:30

Phase 2 Interim Data Evaluating the Combination of Pracinostat and Azacitidine in Patients with Myelodysplastic Syndrome Presented at the 2018 American Society of Hematology Annual Meeting LUGANO, Switzerland and San [...]

NICOX : Number of voting rights as of November 30. 2018

03/12/2018 - 17:46

Nicox SA Société anonyme with a registered capital of € 29,715,320 Head Office: DRAKKAR D 2405 route des Dolines 06560 Valbonne Sophia-Antipolis R.C.S. GRASSE 403.942.642 On December 3, 2018, MONTHLY PUBLICATION OF THE [...]

NICOX : Nombre de droits de vote au 30 novembre 2018

03/12/2018 - 17:46

Nicox SA Société anonyme au capital de 29 715 320 euros Siège social : DRAKKAR D 2405 route des Dolines 06560 Valbonne Sophia-Antipolis R.C.S. GRASSE 403.942.642 Le 3 décembre 2018, PUBLICATION MENSUELLE DU NOMBRE D' [...]

Affimed Presents Data at ASH 2018 Substantiating Opportunity for AFM13 as Mono- and Combination Therapy in CD30-Positive Tumors

03/12/2018 - 17:30

- Data Confirm Clinical Single-Agent Activity of AFM13 in CD30-Positive Lymphoma with Cutaneous Presentation and Doubled Complete Response Rate of AFM13 in Combination with Keytruda ® (Pembrolizumab) in Hodgkin Lymphoma [...]

Ossur Hf : Transactions in relation to share buyback program

03/12/2018 - 17:00

Announcement no. 69/2018 3 December 2018 Transactions in relation to share buyback program On 9 October 2018, Össur hf. initiated a share buy-back program, see Company announcement no. 59/2018. The purpose of the share [...]

Agios Presents Updated Data from the Ivosidenib Phase 1 Dose-Escalation and Expansion Trial in IDH1 Mutant Positive Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Ineligible for Standard Treatment and Myelodysplastic Syndrome (MDS)

03/12/2018 - 16:30

– Single Agent Ivosidenib Demonstrated CR+CRh Rate of 42.4% and Overall Response Rate (ORR) of 57.6% in Newly Diagnosed AML Patients Ineligible for Standard Treatment – – Supplemental New Drug Application for Single [...]

Allogene Therapeutics Presents Data from Preclinical Study of ALLO-715 (anti-BCMA) Demonstrating Allogeneic CAR T Potential in Multiple Myeloma at the 2018 ASH Annual Meeting

03/12/2018 - 16:30

Preclinical Data Supports Advancement of ALLO-715 into Phase 1 in Multiple Myeloma ALLO-715 Investigational New Drug Application and Initiation of a Phase 1 Trial Planned for 2019 SOUTH SAN FRANCISCO, Calif., Dec. 03, [...]

Agios Announces Updated Data from Phase 1 Study of Ivosidenib or Enasidenib in Combination with Standard Induction and Consolidation Chemotherapy in Newly Diagnosed AML Patients With an IDH Mutation

03/12/2018 - 16:15

– 91% CR+CRi/CRp Rate in Ivosidenib-treated Patients with De Novo AML and 53% in Ivosidenib-treated Patients with Secondary AML – – 77% CR+CRi/CRp Rate in Enasidenib-treated Patients with De Novo AML and 64% in [...]